- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05727319
Advances in Imaging to Assess Response in Pancreatic Cancer (AIR-PANC) (AIR-PANC)
Advances in Imaging to Assess Response in Pancreatic Cancer (AIR-PANC): A Single Centre Feasibility Study
The goal of this observational study is to determine the feasibility of acquiring serial MRI images for longitudinal analysis in pancreatic ductal adenocarcinoma (PDAC) patients. The main question it aims to answer:
Is it feasible to acquire baseline and repeat MR images in Radiotherapy treatment position?
Study Overview
Status
Conditions
Detailed Description
PDAC is one of the leading causes of cancer deaths in the UK, with the number of deaths resembling the number of new cases each year. Long term survival is poor, with around 3% of patients alive at 5 years, reducing to 1% at 10 years. Outcomes have shown minor improvement over the past few decades, with little impact in survival being achieved. This is a worldwide problem, with pancreatic cancer being 7th cause of cancer death.
Although progress has been made in terms of assessing the molecular profiling of pancreatic cancer, there has been little progress in some of the clinical aspects e.g. optimal radiological assessment to stratify patients. Currently imaging criteria following neo-adjuvant treatment has been shown to be sub-optimal in accurately defining response to treatment, which may prevent patients from receiving the treatment that gives them the best outcomes. The emerging paradigm in using pre-operative treatment (chemotherapy +/- RT) to improve outcomes for patients is likely to become the standard of care, increasing the need for advanced imaging assessments that accurately stratify patients by enhancing what is currently assessable on morphological images.
Quantified imaging biomarkers (QIMB) and radiomics are a highly promising area of RT research which will enhance the future direction of personalised treatment. Groups have used said research to examine tumour response; predict toxicity; and adapt RT for some anatomical sites. However, this area of research is particularly challenging in the abdomen, where many uncertainties exist, e.g. motion of pancreas and organs at risk; and poor image quality due to motion artefacts on imaging. New promising data is emerging from centres where patients are being treated with MR guided radiotherapy (MRgRT) systems. These include serial image analysis using delta radiomics that can predict early response in tumour; and feasibility of acquiring functional MR throughout treatment that shows apparent diffusion coefficient (ADC) change in tumour and a correlation to response. Very little work has been done to measure ADC changes during RT and this is where potential to adapt RT lies.
Diffusion MRI (dMRI) allows increased monitoring of functional changes during or post RT by providing information on the biological characteristics of tissue. Recent data even shows promise in the correlation of treatment outcome to ADC measured or compared pre and post RT, by correlating change in ADC to pathologic response; as a tool to predict patients likely to have a successful R0 resection; and in predicting patients who will not respond to CRT and may require a different disease management.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Aileen Duffton
- Phone Number: 01413017428
- Email: aileen.duffton@ggc.scot.nhs.uk
Study Locations
-
-
-
Glasgow, United Kingdom, G120YN
- Recruiting
- Beatson West of Scotland Cancer Centre
-
Contact:
- Aileen Duffton - Chief Investigator
- Phone Number: 01413017428
- Email: aileen.duffton@ggc.scot.nhs.uk
-
Contact:
- Derek Grose - Principal Investigator
- Phone Number: 01413017070
- Email: derek.grose@ggc.scot.nhs.uk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Histologically confirmed localised PDAC -as determined by the West of Scotland Hepato-Pancreatobiliary (HPB) MDT
- Scheduled to undergo RT +/- chemotherapy
- 18 years of age or older
- Measurable disease on imaging
- Able to give written informed consent
- Patients willing and able to comply with the protocol for the duration of the study
Exclusion Criteria:
- Distant metastatic disease
- Other severe or uncontrolled systemic disease or evidence of any other significant disorder or lab finding that makes it undesirable for the patient to participate in the study, as determined by the treating physician.
- History of physical or psychiatric disorder that would prevent informed consent and compliance with protocol
- Major surgery within 28 days prior to trial entry
- Any contraindication to MR
- MRI unsafe implants, ferrous metal in the body, insufficient information on previous surgeries, MRI conditional implants where the conditions cannot be met (e.g. pacemakers).
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reproduciblity
Time Frame: 18 months
|
The proportion of patients who have successfully completed acquisition of a baseline and week 1 repeat scans
|
18 months
|
Volumetric and functional feasibility
Time Frame: 18 months
|
The proportion of patients where volumetric and functional measurements are reproducible between baseline and repeat scans
|
18 months
|
Region of interest quantifiability
Time Frame: 18 months
|
The proportion of patients where a region of interest can be created and quantified imaging parameters (e.g.
ADC) can be extracted on baseline and repeat imaging
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Image parameter extraction
Time Frame: 18 months
|
The proportion of patients where a region of interest (ROI) can be created and quantified imaging parameters (e.g.
ADC) can be extracted on baseline and repeat imaging
|
18 months
|
Morphological data
Time Frame: 18 months
|
The proportion of patients where change in ADC pre and post RT correlate to RECIST from SOC to follow up
|
18 months
|
Reproducibility of motion corrected/gated image acquisition
Time Frame: 18 months
|
The proportion of patients where key features can be tested on larger data sets
|
18 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Metabolic changes
Time Frame: 18 months
|
The proportion of patients with RT induced metabolic changes that are predictive of outcomes in PDAC
|
18 months
|
Translational
Time Frame: 18 months
|
The proportion of patients where transcriptomic subtypes of pancreatic cancer to baseline dMRI and changes of dMRI post RT as a discovery biomarker analysis of response prediction
|
18 months
|
Prognostic tool discernment
Time Frame: 18 months
|
The proportion of patients where the systemic metabolic fingerprint of the tumour can be used as a prognostic tool to discern response to radiotherapy
|
18 months
|
Characterisation
Time Frame: 18 months
|
The proportion of patients where the processing of FFPE tissue samples with the Human Whole Transcrtiptome TempO-seq assay for 10 patients can be successfully collected and analysed
|
18 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Aileen Duffton, Chief Investigator
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- GN21ON523
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Ductal Adenocarcinoma
-
Roswell Park Cancer InstituteNot yet recruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal Adenocarcinoma and other conditionsUnited States
-
Georgetown UniversityERYtech PharmaActive, not recruitingMetastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Gilead SciencesTerminatedPreviously Untreated Pancreatic Ductal Adenocarcinoma | Relapsed/Refractory Pancreatic Ductal AdenocarcinomaUnited States
-
SOFIERecruitingFAP | PDAC - Pancreatic Ductal AdenocarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Metastatic Pancreatic Cancer | Metastatic Pancreatic Ductal Adenocarcinoma | Primary Pancreatic Ductal AdenocarcinomaUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Bristol-Myers SquibbRecruitingPancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)United States
-
UMC UtrechtDutch Pancreatic Cancer Group (DPCG)Enrolling by invitationResectable Pancreatic Ductal Adenocarcinoma | Recurrent Pancreatic Ductal AdenocarcinomaNetherlands
-
OHSU Knight Cancer InstituteGenentech, Inc.; Oregon Health and Science University; American Association for... and other collaboratorsRecruitingStage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal Adenocarcinoma | Unresectable Pancreatic Ductal AdenocarcinomaUnited States
-
Sohag UniversityCompletedPancreatic Adenocarcinoma